Notification for the Submission of Safety and Efficacy of FDC permitted to manufacture but not approved by DCGI
According to DCG (I) file No. 4-01/2013-DC (Misc 13-PSC) dated 15 Jan 2013, In respect of FDC Falling under definition of “New Drug” licensed by state licensing Authorities before 1.10.12, without the permission of DCG (I), it has been decided that the DCG (I) will ask all the state drug controllers to ask the concerned manufacturers to prove the Safety and Efficacy of such FDCs before CDSCO within a period of 18 months, failing which such FDCs will be considered for being prohibited for manufacture and marketing in the country.
The new FDCs, if any, licensed by the state licensing authorities after 01.10.12 without approval of DCG(I), the same will be considered for being prohibited for manufacture and marketing in the country.
Recent Posts
How to Manufacture Class A & B Medical Devices in India: State FDA License Guide
A quick guide on the Class A & B Medical Device manufacturing license — covering State FDA rules, Form MD-3/MD-5, fees, and timelines for manufacturers. Every manufacturer entering India’s..
Importing Small Quantities of Cosmetics for R&D in India: NOC Requirements
A brief guide on Cosmetic import NOC India — covering when small quantity Cosmetic import for R&D testing bypasses full registration under Cosmetic rules 2020. Not every Cosmetic shipment into I..
The Cosmeceuticals Grey Zone: When a Cosmetic Claim Risks Becoming a Drug Claim
“Cosmeceutical” is a popular marketing word. It suggests something more powerful than an ordinary Cosmetic — a product that treats skin condition, not just improves appearance. The problem is th..
Get In Touch With Our Team
-
Email: contact@cliniexperts.com
-
Timings: 9 am to 6 pm (Monday to Friday)
-
Location: India: Delhi, Bangalore Global: USA, Singapore